IP Library › Granted Patent US 9,513,292
Granted Patent B2
US 9,513,292 · App. 14/579,474 · Granted Dec 6, 2016

Method for diagnosing cancer by detecting GPC3

Inventors: Hiroyuki Aburatani (Tokyo, JP); Yutaka Midorikawa (Tokyo, JP); Kiyotaka Nakano (Shizuoka, JP); Iwao Ohizumi (Shizuoka, JP); Yukio Ito (Tokyo, JP); Susumu Tokita (Tokyo, JP)
Assignee: Perseus Proteomics Inc.
G01N33/57438G01N33/57488G01N33/57492G01N2333/4722G01N2400/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,513,292
App. No.
14/579,474
Granted
Dec 6, 2016
Kind
B2
Abstract

Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.

Claims (5)

1. A sandwich ELISA kit for diagnosing a possible presence of GPC3 protein expressing hepatic cancer in a human subject by detecting a soluble GPC3 protein level in a test sample obtained from the human subject, comprising two types of anti-GPC3 antibodies each recognizing the N-terminal peptide of GPC3, wherein the N-terminal peptide of GPC3 is a peptide fragment consisting of the amino acid sequence from the 1st amino acid to the 358th amino acid of SEQ ID NO: 4.

2. The kit of claim 1 , wherein the test sample is selected from the group consisting of blood, serum and plasma.

3. The kit of claim 2 , wherein the detected soluble GPC3 level in the test sample is greater than a control level of GPC3 in normal non-cancerous blood, serum or plasma, indicates the possible presence of GPC3 protein expressing hepatic cancer in the human subject.

4. The kit of claim 1 , comprising an anti-GPC3 antibody immobilized on a carrier and an anti-GPC3 antibody labeled with a labeling substances.

5. The kit of claim 4 , wherein the labeling substances are biotin.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NEED TO ADD AN ASSIGNMENT AND CORRECT INVENTOR'S NAMES PREVIOUSLY RECORDED AT REEL: 035068 FRAME: 0771. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 12, 2016
From: ABURATANI, HIROYUKI; ITO, YUKIO; MIDORIKAWA, YUTAKA; NAKANO, KIYOTAKA; OHIZUMI, IWAO; TOKITA, SUSUMU
To: PERSEUS PROTEOMICS INC.
Reel/Frame 040885/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2015
From: ABURATANI, HIROVNKI; ITO, YUKIO; MIDORIKAWA, YUTAKA; OHIZUMI, IWAO; NAKANO, KIYOTAKA
To: PERSEUS PROTEOMICS INC.
Reel/Frame 035068/0771 →
Continuity (2)
Division 10526508
Related Publication 20150132782A1 · May 14, 2015